The month of July 2025 witnessed significant funding rounds in the biotech industry, with companies such as Abivax, MapLight Therapeutics, Everest Medicines, and Soleno Therapeutics securing substantial investments across private and public funding categories. Particularly, these companies made headlines for their remarkable fundraising activities, emphasizing the ongoing financial support within the biotech sector.
Private Biotech Funding Rounds in July 2025
MapLight Therapeutics led the private funding rounds by securing $372.5 million in series D financing, aimed at advancing their lead program for schizophrenia and Alzheimer’s disease psychosis. Artbio and Avalyn Pharma also raised notable amounts, with $132 million and $100 million respectively, to further their innovative treatments for cancer and pulmonary fibrosis. Notably, North America dominated the private funding landscape, raising $768 million from seven rounds, while Europe and Asia-Pacific followed closely with substantial investments in biotech companies.
Public Biotech Funding Rounds in July 2025
Abivax stood out in the public funding rounds, closing a $747.5 million public offering to support its operations until late 2027. Everest Medicines and Soleno Therapeutics also made significant strides with $200 million each, focusing on global research and development, commercialization efforts, and product launches. The fundraising activities in July highlighted the diversity of therapeutic areas in biotech, with oncology and inflammatory diseases being the key focus for investors, demonstrating the industry’s commitment to addressing critical medical needs.
Key Takeaways:
– MapLight Therapeutics, Artbio, and Avalyn Pharma were among the top private biotech funding recipients in July 2025, securing substantial investments for their innovative programs.
– Abivax, Everest Medicines, and Soleno Therapeutics led the public biotech funding rounds, emphasizing the importance of financial support in advancing novel therapies.
– The funding distribution across different therapeutic subsectors showcased a balanced investment approach, with a focus on areas such as oncology, neurological conditions, and inflammatory diseases.
– Despite fluctuations in private fundraising, public companies experienced a robust month in July 2025, signaling continued investor confidence in the biotech industry’s growth potential.
Read more on labiotech.eu